← Back to list
08.01.47a, Triamcinolone Acetonide Extended-Release Injectable (Zilretta®)
Effective date
Not stated in the notice
Identified
Jun 19, 2026
Summary
Independence Blue Cross reissued Policy 08.01.47a on 04/01/2026 with no substantive changes to Zilretta® (Triamcinolone Acetonide Extended-Release Injectable) coverage criteria. The policy maintains existing medical necessity requirements for knee osteoarthritis treatment and continues to use HCPCS code J3304. No billing workflow changes are required.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01No immediate action required.
02This is a routine annual reissue with no changes to coverage criteria, billing codes, or prior authorization requirements.
03Billing team should update policy files to the 04/01/2026 version for internal records and reference only.
04Continue applying existing Zilretta® coverage rules without modification.
Codes mentioned
J3304
Original notice
08.01.47a, Triamcinolone Acetonide Extended-Release Injectable (Zilretta®)
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)LowNo effective date · PharmacyMA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)LowEffective Apr 1, 2026 · Pharmacy08.01.47a, Triamcinolone Acetonide Extended-Release Injectable (Zilretta®)LowNo effective date · PharmacyBrowse every Independence Blue Cross change in the policy list